Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 Next >
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in Aegis Virtual Conference on February 24, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides 2021 Year End Summary
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the Jefferies London Healthcare Conference
From Cybin Inc.
Via Business Wire
Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Granted DEA Schedule I Manufacturing License
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Hosting Research and Development Briefing on November 8, 2021
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Files an International Patent Application Covering Psychedelic Delivery Methods
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.